SIRT1 as a Promising Novel Therapeutic Target for Myocardial Ischemia Reperfusion Injury and Cardiometabolic Disease

Author(s): Dong Han, Jinda Wang, Sai Ma, Yundai Chen, Feng Cao*

Journal Name: Current Drug Targets

Volume 18 , Issue 15 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Cardiovascular diseases, especially ischemic heart disease and cardiometabolic disease, remain to be the leading cause of morbidity and mortality worldwide. Despite recent progress in diagnostic and therapeutic approaches, the incidence of cardiovascular disease is still rising. Therefore, alternative favorable treatment is urgently needed to rescue the fast growing numbers of patients.

Objective: Herein we aimed to review the relevant role and explore the possibility of SIRT1 as a promising target for protection of heart from ischemia/reperfusion injury and cardiometabolic diseases.

Results: The activation of SIRT1 participates in a variety of important metabolic and physiologic processes including stress resistance, metabolism, apoptosis and energy balance in heart ischemia injury and cardiometabolic disease.

Conclusion: Current medication targeting SIRT1 may represent a new therapeutic trend for the prevention of cardiovascular disease that is related to energy balance and metabolism.

Keywords: SIRT1, ischemia reperfusion injury, metabolic disease, heart, resveratrol, therapy, target.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 18 October, 2017
Page: [1746 - 1753]
Pages: 8
DOI: 10.2174/1389450116666150630110529
Price: $65

Article Metrics

PDF: 33